We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Dci4.2
D-Chiro-Inositol Research
Mostly mechanism / observational
21 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most D-Chiro-Inositol studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 2011–2026 with a typical study size of 92 participants.
Based on 21 studies · 4 meta-analyses · 7 RCTs · 592 total participants
Confidence
High confidence
By outcome
Women's health
Mostly mechanism / observational19 studies
Glucose & metabolicInositols support insulin sensitivity · 8-12 weeks
Mostly mechanism / observational12 studies
Active research area
16 studies in the last 5 years · Latest meta-analysis: 2026
201120182026
1Meta-Analysis2017
Morley LC, Tang T, Yasmin E, Norman RJ, Balen AH · Cochrane Database Syst Rev (2017)
Nordio M, Proietti E · Eur Rev Med Pharmacol Sci (2012)
4RCT2011
Unfer V, Carlomagno G, Rizzo P, Raffone E, Roseff S · Eur Rev Med Pharmacol Sci (2011)
5RCT2015
Formuso C, Stracquadanio M, Ciotta L · Minerva Ginecol (2015)
6RCT2014
Malvasi A, Casciaro F, Minervini MM, Kosmas I, Mynbaev OA, Pacella E · Eur Rev Med Pharmacol Sci (2014)
7Review2024
In plain English: More evidence-based data are needed to definitively establish the usefulness of Myo, the appropriate dosage, and to support the use of D-chiro-inositol (DCI) or a definitive Myo/DCI ratio.
Moretti C, Bonomi M, Dionese P, Federici S, Fulghesu AM, Giannelli J, Giordano R, Guccione L, Maseroli E, Moghetti P, Mioni R, Pivonello R, Sabbadin C, Scaroni C, Tonacchera M, Verde N, Vignozzi L, Gambineri A. · Journal of endocrinological investigation (2024)
Myo can be preconceptionally added to folic acid in women with a previous neural tube defects (NTD)-complicated pregnancy to reduce the risk of NTDs in newborns.
Myo can be used during pregnancy to reduce the risk of macrosomia and neonatal hypoglycemia in mothers at risk of GDM.
Conclusion This consensus statement provides recommendations aimed at guiding healthcare practitioners in the use of inositols for the treatment or prevention of female reproductive disorders.
In plain English: Our study shows that the food supplement tested is a valid and safe alternative therapeutic approach in the management of MetS and all its resulting risk factors, as its efficacy has been demonstrated across anthropometric, glucose, lipid and hepatic parameters.
Citarrella R, Chianetta R, Amodeo S, Mirarchi L, Licata A, Soresi M, Veronese N, Barbagallo M, Giannitrapani L. · Nutrients (2024)
Fifty-eight subjects with MetS and T2DM or impaired glucose tolerance assuming metformin, were randomly assigned to take a food supplement of glucomannan, D-chiro-inositol, Cinnamomum zeylanicum blume and inulin at a daily fixed dose of 4 g orally for four months.
Body weight, waist circumference, plasma lipid profile (total cholesterol, LDL, HDL and triglyc-erides), plasma glycaemic profile and visceral adiposity index (VAI) were measured at baseline and after four months of supplementation.
Our study shows that the food supplement tested is a valid and safe alternative therapeutic approach in the management of MetS and all its resulting risk factors, as its efficacy has been demonstrated across anthropometric, glucose, lipid and hepatic parameters.
In plain English: The results of the studies show that there is insufficient or controversial evidence to recommend the use of DCI alone, while MYO alone shows positive results and, above all, the MYO/DCI combination is effective when used at a ratio of at least 40:1, but there is enough rationale to further study ratios such as 66:1 to 100:1 as other possible effective combinations.
Lete I, Martínez A, Lasaga I, Centurión E, Vesga A. · Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology (2024)
In this article, we present a narrative review on the use of inositol in the treatment of polycystic ovary syndrome (PCOS).
Of the different inositols that exist, only myo-inositol (MYO) and D-chiro inositol (DCI) have been studied in the treatment of PCOS.
In plain English: These findings show that diet supplementation with inositol may be a promising strategy to address female infertility and sustain a healthy pregnancy.
Placidi M, Casoli G, Tatone C, Di Emidio G, Bevilacqua A. · Biology (2024)
In women with PCOS, the MYO/DCI ratio is lowered to 0:2:1, contributing to elevated androgen production.
By regulating FSH signaling, MYO administration increases the number of high-quality embryos available for transfer in poor responder patients.
Finally, by acting downstream to insulin signaling, inositol administration during pregnancy may represent a novel strategy for counteracting gestational diabetes.
In plain English: The insulin-sensitizing activities of d -chiro-inositol are well understood; however, its potential applications in other fields, in particular obesity and hyperestrogenic/hypoandrogenic disorders in men and women, represent promising avenues of research that require further clinical study.
Dinicola S, Unfer V, Soulage CO, Yap-Garcia MIM, Bevilacqua A, Benvenga S, Barbaro D, Wdowiak A, Nordio M, Dewailly D, Appetecchia M, Aragona C, Espinola MSB, Bizzarri M, Cavalli P, Colao A, D'Anna R, Vazquez-Levin MH, Hernàndez Marin I, Kamenov Z, Laganà AS, Monastra G, Montanino Oliva M, Cenk Özay A, Pintaudi B, Porcaro G, Pustotina O, Pkhaladze L, Prapas N, Roseff S, Salehpour S, Stringaro A, Tugushev M, Unfer V, Vucenik I, Facchinetti F. · Gynecologic and obstetric investigation (2024)
Outcome d -Chiro-inositol acts through a variety of mechanisms, acting as an insulin sensitizer, inhibiting the transcription of aromatase, in addition to modulating white adipose tissue/brown adipose tissue transdifferentiation.
These different modes of action have potential applications in a variety of therapeutic fields, including PCOS, dysmetabolism, obesity, hypoestrogenic/hyperandrogenic disorders, and bone health.
Conclusions d -Chiro-inositol mode of action has been studied in detail in recent years, resulting in a clear differentiation between d -chiro-inositol and its isomer myo-inositol.
In plain English: Inositol supplementation is associated with improvements in biochemical hyperandrogenism in women with PCOS, with evidence of phenotype-dependent variability.
Tienforti D et al. · Clinical endocrinology (2026)
Inositol supplementation was associated with significant reductions in TT (SMD -1.30; 95% CI -2.17 to -0.42), cFT, and FAI, together with an increase in SHBG.
In subgroup analyses, the largest and most consistent reduction in TT was observed among normal-weight women (BMI < 25 kg/m²) (SMD -2.97; 95% CI -3.78 to -2.16), with minimal heterogeneity (I² = 9%).
No significant improvements were detected in overweight or obese women, nor in women with insulin resistance when considered independently of BMI.
In plain English: As our understanding of inositol's role in pregnancy deepens, it may emerge as a valuable supplement to enhance maternal and fetal health outcomes.
Mazzera I, Graziano A, Vizzielli G, Driul L. · Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology (2024)
Inositols are crucial in cellular signal transduction and insulin sensitivity, making them integral to various physiological processes.
Several studies suggest that inositols may contribute to preventing and managing gestational diabetes mellitus (GDM).
MI, in particular, has shown promise in improving insulin sensitivity and mitigating insulin resistance, thereby influencing glucose metabolism.
In plain English: However, if a treatment based on inositol could be equally effective on different phenotypes of PCOS needs a specific assessment.
Lentini G, Querqui A, Monti N, Bizzarri M. · Drug design, development and therapy (2025)
Expert opinion Inositol-based treatments in PCOS are gaining momentum, demonstrating safety and efficacy greater than those obtained with other pharmacological agents.
The efficacy depends not only on the modulation of insulin sensitivity but also on the direct, steroidogenic effects upon the ovaries.
Adequate adsorption of Inositol is a critical issue, and the association of α-Lactalbumin can significantly overcome this problem.
In plain English: Inositol and vitamin D represent potential options, but more studies are required to elucidate their roles in the management of this condition.
Katyal G, Kaur G, Ashraf H, Bodapati A, Hanif A, Okafor DK, Khan S. · Clinical and experimental reproductive medicine (2024)
This systematic review underscores the importance of investigating inositol and vitamin D within a PCOS management strategy, given the disorder's prevalence and impacts on fertility and metabolic health.
Although these agents show promise, additional research could clarify their mechanisms of action and therapeutic benefits.
This review emphasizes the need for exploration of effective treatments to improve the quality of life among individuals with PCOS.
In plain English: A systematic review/meta-analysis found possible metabolic/ovulatory benefits from inositol in PCOS but concluded the evidence is limited and inconclusive.
Fitz V et al. · J Clin Endocrinol Metab (2024)
Possible metabolic and ovulatory benefit signals for inositols in PCOS
Most evidence is myo-inositol or MI+DCI combinations
Meta-analysis concluded the evidence is LIMITED and INCONCLUSIVE
Gul M, Khan H, Rauf B, Bukhari SMS, Ehtesham E, Malik MO, Shah FA, Alanazi FE, Shah M. · Naunyn-Schmiedeberg's archives of pharmacology (2025)
Both MI plus DCI and metformin significantly improved insulin sensitivity (HOMA-IR, p < 0.001), SHBG levels (p = 0.021), ovarian volume (p < 0.001), and menstrual regularity (p = 0.002), along with BMI, quality of life, and PSS scores (p < 0.001).
Our findings support both MI plus DCI and metformin as effective treatments for PCOS, with each treatment offering specific benefits.
These results highlight the potential for a phenotype-specific tailored therapeutic approach to better manage the complex metabolic, endocrine, and stress-related challenges of PCOS.
In plain English: These findings, while promising, require confirmation in larger prospective trials.
Belchín Fernández P, Calvente V, Gómez Roso MJ, González Expósito E, Silván Bueno A, Aparicio Fluge M, Ordoñez Pérez D. · Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology (2026)
Results The number of retrieved oocytes (21.5 in Group 1 vs. 20.7 in Group 2; p = 0.56) and the metaphase II oocyte rate (72.06% in Group 1 vs. 71.23% in Group 2; p = 0.68) were comparable between both groups.
Notably, Group 1 achieved higher fertilization rates (77.66% vs. 71.61%; p = 0.0314) and a lower proportion of cycles without at least one good-quality blastocyst to transfer (4.35% vs. 17.39%; p = 0.0450).
In addition, both clinical and ongoing pregnancy rates were significantly improved in the supplemented group (54.39% vs. 42.65%; p = 0.0203; 45.61% vs. 36.76%; p = 0.0033).